Atopic Dermatitis – Parents Of Allergic Children http://parentsofallergicchildren.org/ Fri, 14 Jan 2022 21:00:45 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://parentsofallergicchildren.org/wp-content/uploads/2021/06/icon-5.png Atopic Dermatitis – Parents Of Allergic Children http://parentsofallergicchildren.org/ 32 32 Health news roundup: US FDA approves Pfizer drug to treat eczema; US reports case of highly pathogenic avian influenza in wild bird and more https://parentsofallergicchildren.org/health-news-roundup-us-fda-approves-pfizer-drug-to-treat-eczema-us-reports-case-of-highly-pathogenic-avian-influenza-in-wild-bird-and-more/ Fri, 14 Jan 2022 21:00:45 +0000 https://parentsofallergicchildren.org/health-news-roundup-us-fda-approves-pfizer-drug-to-treat-eczema-us-reports-case-of-highly-pathogenic-avian-influenza-in-wild-bird-and-more/ Here is a summary of health news briefs. Peak of Omicron? Experts are hesitant to call time on the variant wave in Europe A rise in coronavirus cases caused by the Omicron variant may have peaked in parts of Europe, but doctors say the impact will continue to be felt across the region, with hospitals […]]]>

Here is a summary of health news briefs.

Peak of Omicron? Experts are hesitant to call time on the variant wave in Europe

A rise in coronavirus cases caused by the Omicron variant may have peaked in parts of Europe, but doctors say the impact will continue to be felt across the region, with hospitals still at risk of dealing with an admissions rush. Health experts and politicians warn against complacency, saying it’s not yet clear whether their data reflects the full impact of the Christmas and New Year holidays, when families came together for long indoor periods and the risk of intergenerational spread of the virus may be greater.

US FDA approves Pfizer drug to treat eczema

The U.S. Food and Drug Administration has approved Pfizer Inc’s drug Cibinqo to treat eczema, a skin condition, the company announced Friday.

EMA lists rare spinal conditions as side effect of AstraZeneca’s COVID-19 vaccine

A European medicines regulator safety group on Friday recommended adding a rare spinal inflammation called transverse myelitis as a side effect of AstraZeneca’s COVID-19 vaccine. The European Medicines Agency’s (EMA) safety committee also recommended that a similar warning be included for Johnson & Johnson’s single-shot vaccine in October, and reiterated the decision on Friday.

UK study finds more Omicron hospitalizations in younger children, but mild cases

Young children and babies are proportionally more likely to be hospitalized with Omicron compared to older children than with previous variants, but cases are still mild, UK researchers said, adding that the overall picture was reassuring. Omicron spread rapidly in Britain and fueled a spike in cases at record levels, although the variant was less severe than previous ones, and high vaccination levels in adults also helped limit the rise hospitalizations. Children are less vulnerable than older adults to COVID-19.

FDA approves expanded use of AbbVie’s arthritis drug to treat eczema

The U.S. Food and Drug Administration has approved expanded use of AbbVie Inc’s arthritis drug to treat eczema, a skin condition, the company announced Friday. Rinvoq’s approval for the treatment of moderate to severe atopic dermatitis, or eczema, was for patients 12 years of age and older who are unresponsive to prior treatment or when the use of other treatments is not recommended .

As Omicron Fuels Rise, US Students Stage Walkouts to Protest In-Person Classes

Hundreds of students in Boston and Chicago walked out of class on Friday to pressure officials to switch to remote learning, as a rise in COVID-19 cases fueled by the Omicron variant disrupts schools across the United States. About 600 students from 11 Boston schools participated, according to the school district. Many students returned to class later, while others returned home after taking part in peaceful protests.

Mexico approves emergency use of Pfizer’s COVID-19 pills

Mexican health regulator COFEPRIS said on Friday it had approved U.S. pharmaceutical company Pfizer’s oral antiviral treatment for COVID-19 for emergency use in adults at mild to moderate risk of complications. Paxlovid, which combines nirmatrelvir and ritonavir in one tablet, will require a prescription, it said in a statement.

US reports case of highly pathogenic avian influenza in wild bird

The United States Department of Agriculture on Friday confirmed the first case of a highly pathogenic strain of avian flu in a wild bird since 2016, in South Carolina. The strain, Eurasian avian influenza H5, was found in a wild American duck in Colleton County, South Carolina, the agency said in a statement. He advised poultry producers to review safety measures to ensure the health of their birds.

US households can order 4 free COVID-19 tests starting Jan. 19 – White House

U.S. households can order four free at-home COVID-19 tests from the COVIDTests.gov website starting Jan. 19 with expected shipping seven to 12 days after ordering, the White House announced Friday. The free test bundle aims to alleviate a shortage of COVID-19 tests across the country amid increased demand during the rapid spread of the Omicron variant.

Burned by COVID supply shortages, hospitals invest in manufacturing masks in the United States

Two days before Christmas, a cargo ship left Mumbai with a mask-making machine bound for Illinois-based OSF HealthCare, which will use the equipment to make its own N95 masks. This is not the hospital group’s first foray into the manufacturing sector. After COVID-19 closed borders in early 2020, shipments from Asia were snuffed out, OSF and some other hospital groups began investing in U.S. production of key supplies, including masks, gowns and essential pharmaceuticals.

(This story has not been edited by the Devdiscourse team and is auto-generated from a syndicated feed.)

]]>
ALLK action is a warning about biopharmaceutical investment https://parentsofallergicchildren.org/allk-action-is-a-warning-about-biopharmaceutical-investment/ Wed, 12 Jan 2022 17:14:11 +0000 https://parentsofallergicchildren.org/allk-action-is-a-warning-about-biopharmaceutical-investment/ As has been shown recently, investing in Allakos (NASDAQ:ALLK) proves the inherent danger in the biopharmaceutical sector. After hitting a high of over $ 157 in 52 weeks, ALLK stock plunged in late December and now sits just above $ 8 per share. Source: luchschenF / Shutterstock.com Biopharmaceutical companies often live and die from the […]]]>

As has been shown recently, investing in Allakos (NASDAQ:ALLK) proves the inherent danger in the biopharmaceutical sector. After hitting a high of over $ 157 in 52 weeks, ALLK stock plunged in late December and now sits just above $ 8 per share.

Source: luchschenF / Shutterstock.com

Biopharmaceutical companies often live and die from the initial success of a single compound. Once a compound receives the green light from the Food and Drug Administration (FDA), the sky is often the limit. The success of an early drug generates a strong source of income, paving the way for future success.

The company can also seek FDA approval for a drug for other conditions, thus increasing the revenue stream of a single compound. But what happens when things go wrong? Allakos recently gave us a preview of what it looks like.

Allakos’ disappointment in December

Allakos describes himself as:

“… a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory and proliferative diseases. The Company’s main antibody, Lirentelimab (AK002), is an investigational drug currently being evaluated in clinical studies, particularly in EGIDs and a phase 2 study in atopic dermatitis.

As I mentioned at the start of this article, the success of a single compound is generally vital for biopharmaceutical companies. In this case, for Allakos, this medicine is Lirentelimab.

Unfortunately for the company, Lirentelimab disappointed in two recent controlled studies. Neither study reached statistical significance on the patient-reported primary endpoints.

The particularly disappointing aspect of the matter is the progress of the matter. The Enigma 2 study was in phase 3 and the Kryptos study was in phase 2 and phase 3. In essence, a long and drawn-out process requiring massive resources produced poor results.

That’s the lesson here.

A marked drop in ALLK stock

It’s not hyperbolic to suggest that ALLK stocks have fallen off a cliff on the news. It literally went from $ 84 to $ 8 overnight.

In short, Allakos has effectively returned to zero. The only hope left for investors is, as Chief Medical Officer Dr Craig Peterson, MD said:

“… The EGID results are surprising and disappointing, we will continue to analyze the data to understand the results and determine the way forward for Liretelimab in EGIDs. At this time, we intend to continue our development efforts with subcutaneous Lirentelimab in atopic dermatitis, spontaneous chronic urticaria and asthma.

It’s a rosy, hopeful prospect to be sure. The disappointing news also points to another consideration to consider when investing in biopharmaceutical companies: Financial data means nothing.

Allakos third quarter results

Allakos released its third quarter results on November 8. Investors with a fleeting understanding of biopharmaceuticals were not surprised. The problems continued to mount at this time.

The company lost $ 62.7 million in the third quarter, down from $ 42.1 million a year earlier. Again, it was not surprising. The business model is pretty straightforward: invest a lot of money up front in developing a drug in order to reap a massive windfall when FDA approval is obtained.

Allakos is very typical in this sense. Of the $ 62.7 million loss in the third quarter, $ 43.6 million was attributable to research and development expenses.

And even if the problems piled up, it didn’t matter. ALLK stock fell when the news broke, but not significantly. At that time, hope was still eternal.

Those Enigma 2 and Kryptos studies were what was important. If they had provided positive news, the ALLK share price would have soared.

ALLK Stock is a warning

There really isn’t much more to say about Allakos. It’s simply a lesson in what happens when things go wrong in pharmaceutical development.

The company still had $ 505.6 million in cash at the end of the third quarter. It can therefore continue to develop Lirentelimab for other applications. But it’s a long game at this point.

Some suggest there is a contrarian opportunity, given that ALLK stock has a target price of $ 50. But that number is likely based on earlier projections of these recently disappointing studies. This implies that its $ 8 price tag makes a lot of sense right now.

As of the publication date, Alex Sirois does not have (directly or indirectly) any position in any of the titles mentioned in this article. The opinions expressed in this article are those of the author, subject to InvestorPlace.com Publication guidelines.

Alex Sirois is an independent contributor to InvestorPlace whose personal equity investing style focuses on long-term, buy and hold stock selections that create wealth. Having worked in multiple industries, from ecommerce to translation to education and using his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.

]]>
STRATA Skin Sciences Reports Preliminary Fourth Quarter and Fiscal 2021 Financial Results https://parentsofallergicchildren.org/strata-skin-sciences-reports-preliminary-fourth-quarter-and-fiscal-2021-financial-results/ Mon, 10 Jan 2022 21:10:00 +0000 https://parentsofallergicchildren.org/strata-skin-sciences-reports-preliminary-fourth-quarter-and-fiscal-2021-financial-results/ HORSHAM, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) – STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to the development, commercialization and commercialization of innovative products for the treatment of skin conditions , today announced preliminary unaudited financial results for the fourth quarter of 2021. Fourth Quarter and Fiscal 2021 Financial Highlights Preliminary […]]]>

HORSHAM, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) – STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to the development, commercialization and commercialization of innovative products for the treatment of skin conditions , today announced preliminary unaudited financial results for the fourth quarter of 2021.

Fourth Quarter and Fiscal 2021 Financial Highlights

  • Preliminary unaudited total revenues are expected to be between $ 8.8 and $ 9.2 million, up from $ 6.7 million in the fourth quarter of 2020

  • Preliminary unaudited total revenue for full year 2021 is expected to be between $ 29.7 million and $ 30.1 million, compared to $ 23.1 million for the full year. year 2020

  • Cash and cash equivalents, including restricted cash, were $ 12.5 million as at December 31, 2021, compared to $ 18.1 million as at December 31, 2020

Fourth Quarter 2021 Operational Highlights

  • Placement of 34 domestic XTRAC systems, resulting in netting systems placed in 890 US dermatologist offices, 18 of which are returns from former owners of excimer devices.

  • Increase in the number of international partner XTRAC clinics to 54, compared to 28 in 2020 and 10 in 2019

  • Conversion of 17 Pharos systems acquired from Ra Medical’s US dermatology business into STRATA’s recurring revenue model

  • Recruitment of Christopher Lesovitz as CFO

“We are pleased with our team’s strong results in the fourth quarter of 2021, which were bolstered by favorable year-end insurance claims and strong business execution by the entire STRATA team. Despite the headwinds of the Delta and Omicron variants, STRATA continued to make significant progress on our strategic initiatives, which was reflected in the quality of our preliminary financial results, ”said Robert Moccia, President and CEO of STRATA Skin Sciences. “After the end of the year, we were also pleased to complete the acquisition of the acne treatment device assets of Theravant Corporation, allowing us to enter the acne care market of 5, $ 5 billion in the United States. The acquisition represents the second purchase of STRATA’s strategic assets in six months, both executed under new management and reinforces STRATA’s position as a global leader in clinical dermatology devices, ”concluded Moccia.

The preliminary unaudited results described in this press release are estimates and are subject to revision until the company releases its complete financial results for the year ended December 2021, which is expected in mid-March.

About STRATA Skin Sciences, Inc.
STRATA Skin Sciences is a dermatology medical technology company dedicated to the development, commercialization and commercialization of innovative products for the in-office treatment of dermatological conditions. Its products include XTRAC® and Pharos® excimer lasers and VTRAC® lamp systems used in the treatment of psoriasis, vitiligo and various other skin conditions.

The company’s proprietary XTRAC and newly acquired Pharos excimer lasers deliver a highly targeted therapeutic beam of UVB light to treat psoriasis, vitiligo, eczema, atopic dermatitis and leukoderma, diseases that affect more than 31 million patients in the United States only. The technology is covered by several patents.

STRATA’s unique business model in the US leverages targeted direct-to-consumer (DTC) advertising to drive awareness and uses its in-house call center and insurance advocacy teams to increase clinic volume dermatological partners of the Company.

Safe harbor
This press release includes “forward-looking statements” within the meaning of the Securities Litigation Reform Act of 1995. Such statements include, without limitation, the plans, objectives, expectations and intentions of the company and may contain words such as ” will, ”“ ”may,” “seek” and “expects,” which suggest future events or trends. These statements, the ability of the Company to launch and sell an acne treatment device and to integrate this device into its product offerings, the ability of the Company to develop, launch and sell products to be developed at the future, the Company’s ability to develop social media marketing campaigns, and the Company’s ability to build a leading franchise in dermatology and aesthetics, are based on the Company’s current expectations and are inherently subject important uncertainties and changes in circumstances. Actual results may differ materially from the Company’s expectations due to financial, economic, business, competitive, market, regulatory, adverse market conditions or supply chain disruptions resulting from the coronavirus and political factors or conditions. affecting the Company and the medical device industry in general, future responses and effects of the COVID-19 pandemic and its variants, including the distribution and efficacy of COVID-19 vaccines, as well as the risks and More specific uncertainties set out in the Company’s SEC reports on Forms 10-Q and 10-K. In view of these uncertainties, some or all of these forward-looking statements may prove to be incorrect or unreliable. Statements contained in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company assumes no obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC information available at www.sec.gov and www.strataskinsciences.com.

Investor contact

]]>
The skin barrier | Herald of the Deccan https://parentsofallergicchildren.org/the-skin-barrier-herald-of-the-deccan/ Sat, 08 Jan 2022 18:37:02 +0000 https://parentsofallergicchildren.org/the-skin-barrier-herald-of-the-deccan/ Due to a rapid drop in humidity that accompanies the onset of winter, moisturizers have become the mainstay of our skin care routine this season. This basic, yet vital component of skin care has been around for a long time, and we’ve all heard the term moisturizer being used inadvertently, but what do we really […]]]>

Due to a rapid drop in humidity that accompanies the onset of winter, moisturizers have become the mainstay of our skin care routine this season. This basic, yet vital component of skin care has been around for a long time, and we’ve all heard the term moisturizer being used inadvertently, but what do we really know about it?

To understand moisturizers, we first need to understand the skin barrier (top layer of the skin) which is made up of skin cells and lipids arranged in a compact pattern of brick and mortar.)

Cholesterol, free fatty acids, and ceramides are lipids found naturally in the skin that help keep the skin soft and supple by preventing transepidermal water loss (PIE). The barrier also prevents foreign substances from entering the skin, which helps ward off infections. Contrary to popular belief, moisturizers do not add water to the skin, instead they reduce transepidermal water loss, provide flexibility to the skin and maintain skin barrier function. Moisturizers are classified into three categories: Emollients such as ceramides, dimethicone and cyclomethicone hydrate and improve the softness and suppleness of the skin. Occlusives are oils such as petrolatum, paraffin, and mineral oils that form a coating on the surface of the skin and prevent water loss. Humectants, such as hyaluronic acid, glycerin, and ammonium lactate, absorb water from the inner layers of the skin or the environment (provided there is high humidity). When you look at the ingredients on the labels of most moisturizers these days, you’ll notice that they contain a blend of all three ingredients that work together.

Hydration may seem like a new trend, but it’s been around for centuries. Cleopatra, the Egyptian queen, is said to have used olive and palm oils to hydrate her skin, which are vegetable oils rich in linoleic acid and are still used today. Coconut oil applied 20 minutes before a shower can help prevent transepidermal water loss, promote skin barrier homeostasis and also has anti-inflammatory properties. Other herbal moisturizers that prevent TEWL include cocoa butter, shea and jojoba oils.

When it comes to moisturizing formulations, there are fluid, non-greasy, oil-in-water lotions that are suitable for almost all skin types and can be used year-round, as well as more water-in-oil creams. thick. which are best suited for winter and dry skin such as atopic dermatitis.

The application procedure is the same regardless of the type of moisturizer. A moisturizer should be applied liberally to clean, damp skin, in the direction of the hair follicles, within 3 minutes of a short shower with lukewarm water. In winter, it is ideal to reapply it 2-3 times a day.

An ideal moisturizer should be hypoallergenic, fragrance-free, and non-comedogenic, as well as address any specific skin concerns you might have, and as you might expect, your dermatologist is the right person to choose it for you.

(The author is a dermatologist.)


Source link

]]>
Rx Topical Dermatology Drug Delivery Market Advances, Behavior, Challenges, Opportunities, Top Companies and Forecast 2028 – Industrial Computing https://parentsofallergicchildren.org/rx-topical-dermatology-drug-delivery-market-advances-behavior-challenges-opportunities-top-companies-and-forecast-2028-industrial-computing/ Fri, 07 Jan 2022 17:23:20 +0000 https://parentsofallergicchildren.org/rx-topical-dermatology-drug-delivery-market-advances-behavior-challenges-opportunities-top-companies-and-forecast-2028-industrial-computing/ DBMR has added a new report titled Rx Dermatology Topical Drug Delivery Market with data tables for historical and forecast years represented by discussions and charts spread across pages with easy to understand detailed analysis. This research report saves time while adding credibility to the work that ruins business development. The report assists all sizes […]]]>

DBMR has added a new report titled Rx Dermatology Topical Drug Delivery Market with data tables for historical and forecast years represented by discussions and charts spread across pages with easy to understand detailed analysis. This research report saves time while adding credibility to the work that ruins business development. The report assists all sizes of organizations by providing informed choices on different perspectives regarding business. This statistical survey report contains an available section and all its related organizations with their profiles, which gives important information related to their perspective regarding accounts, article portfolios, growth strategies and methodologies presentation and business. The report is exceptionally valuable for associations in every business circle to establish better choices, to answer even the most difficult business questions and thus decrease the risk of disappointment.

This report focuses on scientific market classification, local examination, opportunity assessment, and vendor survey to help in-depth assessment of the global market. This review will help advertising members have a good understanding of future market and industry improvement. The critical findings and suggestions in this report highlight important moderate industry models in the global market, thereby enabling market players across the value chain to foster successful long-haul methodologies. Features related to key business needs help organizations realign their business methodologies. To make the review report comprehensive, Porter’s Five Powers Investigation and SWOT Review has been used in a viable fashion.

The dermatological topical drug delivery market is expected to witness the market growth during the forecast period of 2020 to 2027. Data Bridge Market Research analyzes that the market is growing with a CAGR of 4.9% over the course of forecast period from 2020 to 2027 and is expected to reach USD 20,903.98 million by 2027. Highly developed healthcare infrastructure capable of adopting updated technologies in United States is driving the market growth in the market. region.

Get Sample Report + All Related Charts & Charts (With COVID 19 Analysis) @https: //www.databridgemarketresearch.com/request-a-sample/? Dbmr = us-rx-dermatology-topical-drug-delivery- market & pm

Major players covered in the report are Pfizer Inc, LEO Pharma A / S, BIOFRONTERA AG, GlaxoSmithKline plc, Galderma Laboratories, LP, Almirall, SA, Mayne Pharma Group Limited, Novartis AG, Teva Pharmaceutical Industries Ltd, Allergan, among others global. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Various factors are driving the dermatology topical drug delivery market such as increasing incidence of skin disorders, development of healthcare infrastructure, medical facilities and also equal access to healthcare facilities for all .

This Dermatology Topical Drug Delivery market report provides market share details, new developments and product pipeline analysis, impact of national and localized market players, opportunities analysis in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the market analysis and scenario, contact us for an analyst brief, our team will help you create a revenue impact solution to achieve the desired goal.

Scope and Market Size of Topical Drug Delivery in United States

The Rx Dermatology Topical Drug Delivery market is segmented on the basis of product type, drug class, application, category, end user, and distribution channel. Growth among segments helps you analyze growth niches and strategies to approach the market and determine your main application areas and the difference in your target markets.

  • On the basis of product type, the market is segmented into semi-solid, liquid, solid. In USA, the semi-solid segment is expected to dominate the market, as semi-solid preparations are more stable and have better effect compared to solid liquid in treating skin diseases.
  • On the basis of drug class, the market is segmented into topical corticosteroids, antiseptics, anti-acne, anti-inflammatory, antibacterial, antifungal, antihistamines, erythromycin, wound healing agents, others. In the United States, the topical corticosteroid segment is expected to dominate the market as topical corticosteroids are widely used in the treatment of various skin diseases such as acne, antiseptics and antibacterials among others.
  • On the basis of application, the market is segmented into Atopic Dermatitis, Hyperpigmentation, Skin Cancer, Onychomycosis, Hydradenitis Suppurativa, and others. In the United States, the dermatitis segment is expected to dominate the market as there is an increasing incidence of dermatitis according to the National Aczema Association, 7.3% of adults have atopic dermatitis.
  • On the basis of category, the market is segmented into branded generics. In the United States, the branded segment is expected to dominate the market, as the brand name drugs offer better therapeutic effect compared to generic drugs. Brand name drugs are also helpful for the rapid cure of illnesses compared to generic drugs.
  • On the basis of the end user, the market is segmented into home care, hospitals, specialty clinics, etc. In the United States, the home care segment is expected to dominate the market due to the growing awareness of skin diseases, which is boosting the home care treatment facilities over others.
  • On the basis of the distribution channel, the market is segmented into retail pharmacy and pharmacy, hospital pharmacy, online pharmacy, etc. In the United States, the retail drugstore and drugstore segment is expected to dominate the market as dermatologic drugs are readily available in retail drug stores and drugstores. In addition, these pharmacies and retail pharmacies are easily accessible to people in this region.

For More Information Get FREE Detailed Table of Contents @https: //www.databridgemarketresearch.com/toc/? Dbmr = us-rx-dermatology-topical-drug-delivery-market & pm

Country Level Analysis of Rx Dermatology Topical Drug Delivery Market

The Rx Dermatologic Drugs Topical Administration market is analyzed and market size information is provided by country, product type, drug class, application, category, end user, distribution channel, and country as shown below- above.

Country Covered in the Topical Rx Dermatologic Drug Delivery Market report is United States

The United States dominates the Rx dermatology topical drug delivery market due to the transformation of healthcare infrastructure across the country.

The country section of the Rx Dermatology Topical Drug Delivery market report also provides individual factors impacting the market and changes in market regulations at the national level impacting the current and future trends of the drug. Marlet. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the main indicators used to forecast the market scenario for each country. In addition, the presence and availability of global brands and the challenges they face due to significant or scarce competition from local and national brands, the impact of sales channels are taken into account while providing a forecast analysis of country data.

Growing prevalence of skin diseases

The Rx Dermatology Topical Drug Delivery market also provides you with detailed market analysis for each country, the growth of installed base of different types of products for the Rx Dermatology topical drug delivery market, the impact of technology utilizing lifeline curves and changing industry regulatory scenarios and their impact on the Topical Drug Delivery in Rx Dermatology Market. Data is available for the historical period 2010 to 2018.

Purchase this report (can be used by entire organization across the globe + downloadable and printable PDF + 30 + countries) @https: //www.databridgemarketresearch.com/inquire-before-buying/? Dbmr = us-rx- dermatology-topical -drug-delivery-market & m

Competitive Landscape and Rx Dermatology Topical Drug Delivery Market Share Analysis

The competitive landscape of the Rx dermatology topical drug delivery market provides details by competitor. Details included are company overview, company finances, revenue generated, market potential, investment in research and development, new market initiatives, global presence, locations and production facilities, company strengths and weaknesses, product launches, clinical trial pipelines, brand analysis, product approvals, patents, product breadth and breadth, application dominance, technological lifeline curve. The above data points provided relate only to the focus of the companies in the Topical Rx Dermatology Drug Delivery market.

For example,

  • In January 2019, Biofrontera AG was awarded the United States Food and Drug Administration (FDA) for increasing batch production of Ameluz to 35 kg, compared to 7 kg in previous years. Biofrontera AG has also received approval from the EMA. With this approval, the company has improved its product portfolio in the market.
  • In December 2016, Pfizer Inc. received approval from the United States Food and Drug Administration (FDA) for the product named EUCRISATM (crisaborole) 2% ointment. This product is mainly used in the treatment of atopic dermatitis. With this product launch, the company enhanced its brand portfolio and brand image in the market.

About the Data Bridges Market Research:

An absolute way to predict what the future holds is to understand the trend today!

Data Bridge has established itself as an unconventional, neoteric market research and consulting company with an unprecedented level of resilience and integrated approaches. We are committed to finding the best market opportunities and providing effective information for your business to thrive in the market. Data Bridge strives to provide appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge strives to create satisfied customers who rely on our services and rely on our hard work with certainty. We’re happy with our glorious 99.9% customer satisfaction rating.

Contact:

Market research on data bridges
United States: +1 888 387 2818
UK: +44 208 089 1725
Hong-Kong: +852 8192 7475
E-mail:
[email protected]


Source link

]]>
Recon: FDA clears Pfizer recall for 12-15 year olds; Teva found responsible in opioid lawsuit in New York https://parentsofallergicchildren.org/recon-fda-clears-pfizer-recall-for-12-15-year-olds-teva-found-responsible-in-opioid-lawsuit-in-new-york/ Mon, 03 Jan 2022 21:11:04 +0000 https://parentsofallergicchildren.org/recon-fda-clears-pfizer-recall-for-12-15-year-olds-teva-found-responsible-in-opioid-lawsuit-in-new-york/ Posted on January 03, 2022 | Through Joanne S. Eglovich Welcome to Regulatory Reconnaissance, your daily briefing on regulatory news and intelligence. Focus: United States FDA clears booster shots for 12-15 year olds (NYTimes) (STAT) (Reuters) (WashingtonPost) FDA clears new Merck Covid-19 pill despite scientists’ concerns over mechanism of action (Endpoints) FDA clears Pfizer’s first […]]]>

Posted on January 03, 2022 | Through Joanne S. Eglovich

Welcome to Regulatory Reconnaissance, your daily briefing on regulatory news and intelligence.

Focus: United States

  • FDA clears booster shots for 12-15 year olds (NYTimes) (STAT) (Reuters) (WashingtonPost)
  • FDA clears new Merck Covid-19 pill despite scientists’ concerns over mechanism of action (Endpoints)
  • FDA clears Pfizer’s first at-home pills to treat Covid-19 (Endpoints)
  • Interval between second injection and booster of Moderna COVID-19 vaccine another six months -FDA (Reuters)
  • FDA approves drug to treat and help prevent types of blood clots in certain pediatric populations (FDA)
  • FDA adds another OK drug to cap record-breaking 2021 win list (endpoints)
  • US FDA new novel approvals jumped to 60 in 2021; CDER authorized 50 new agents, refused 18 (pink sheet)
  • Roche gets US green light for rapid home COVID test (Fierce)
  • A year overdue, but Novartis finally steered inclisiran towards FDA approval. will it sell? (End points)
  • Reaching new drug approval record, FDA gives green light to yet another atopic dermatitis candidate (Endpoints)
  • Following Tezspire US Approval, Amgen To Add Filler Line In Ireland (Endpoints)
  • Months after missing PDUFA date, FDA slaps Takeda’s old drug Shire for eosinophilic esophagitis (endpoints)
  • New York Jury Holds Teva Pharmaceuticals Accountable in Opioid Crisis (STAT) (NYTimes)

Focus: international

  • End of year message from Emer Cooke (EMA)
  • EMA recommends authorization of Nuvaxovid in the EU (EMA)
  • COVID-19: the EMA recommends the authorization of the antibody drug Xevudy (EMA
  • EFPIA not impressed with proposals to tackle drug shortages in the EU (pink sheet)
  • Omicron evades immunity better than Delta, Danish study finds (Reuters)
  • Omicron “clearly softer”; new measures not necessary, according to Britain’s Johnson (Reuters)
  • Israel now offers fourth covid snapshot to anyone 60 and over (Washington Post)
  • India vaccinates 3.8 million adolescents in new COVID-19 vaccination campaign (Reuters
  • UAE demands coronavirus booster injections for citizens wishing to travel abroad (Washington Post)

Coronavirus pandemic

  • Studies suggest why Omicron is less severe: it spares the lungs (NYTimes)
  • As Omicron spreads, officials wonder what it means to be ‘fully vaccinated’ (NYTimes)
  • As home testing rises, doubts rise over the accuracy of public Covid counts (NYTimes)
  • J&J Recall Offers Strong Protection Against Critical Illnesses From Omicron, Study Finds (NYTimes)
  • Novavax breaks another commitment for its Covid-19 vaccine. And the United States would now worry about Global Goals (Endpoints)
  • WHO official looks at Covid, vaccines and mistakes (STAT)
  • Beyond the number of cases: what Omicron teaches us (STAT)
  • Omicron winter forecast: experts consider various scenarios, worse and worse (STAT)

Pharma & Biotech

  • Novartis Unlocks $ 1.5 Billion Buyout for Gene Therapy – Boosts Arsenal Against Retinal Disease (Endpoints)
  • Not everyone is buying it, but everyone is definitely talking about a new Biogen buyout report (Endpoints)
  • AstraZeneca appeals to Ionis to join host of companies battling rare heart disease in billion-dollar deal worth biobucks (Fierce)
  • In ‘baffling’ disappointment, BridgeBio’s heart drug misses the primary focus of the pivotal study (STAT)
  • Low-key RNAi player lands on HKEX after modest $ 50 million IPO (End points)

Medtech

  • FDA Releases Draft Guidelines for Closed-Loop Physiological Monitoring Devices (MedtechInsight)
  • Final FDA Guidelines for BPH Device Studies Suggest Rapid Patient Follow-up (MedtechInsight)
  • FDA proposes framework to assess credibility of devices designed with computer modeling and simulation (MedtechInsight)
  • More pre-development Medtech work must be in Singapore’s sights
  • MTI Outlook 2022: The Post-COVID Mantra for Medical Technologies: Prioritize, Optimize and Modernize (MedtechInsight)
  • Minute Insight: Quidel and Labcorp end a great year for IVD agreements with major acquisitions (MedtechInsight)
  • Omicron Variant: Tide Labs Solves False Negative Problem With COVID-19 Testing (MedtechInsight)
  • A possible screening tool for cervical cancer? A menstrual pad (Washington Post)
  • Three missing pieces that the digital therapeutic sector needs to succeed in 2022 (STAT)

Government, Regulation and Legal

  • 2022 trials to watch: Opioids, Oracle and Theranos Redux (Law360)
  • Holmes Jury Asks to Rehear Former CEO’s 2013 Investor Appeal (Law360)
  • 5e Circ. Will Not Revive Walmart’s Opioid Lawsuit Against Federal Government (Law360)
  • Will the Biden administration use the “walk” to protect prostate cancer patients from excessive drug prices? (STAT)

Regulatory Recon is a daily intelligence briefing for the regulatory affairs space, bringing you the best regulatory, biopharmaceutical and medical news from around the world.

Inclusion of a story in the Regulatory Recon does not imply endorsement by Regulatory Focus or RAPS.

© 2022 Society of Regulatory Affairs Professionals.



Source link

]]>
How To Do Microdermabrasion At Home – Expert Advice https://parentsofallergicchildren.org/how-to-do-microdermabrasion-at-home-expert-advice/ Fri, 31 Dec 2021 15:01:13 +0000 https://parentsofallergicchildren.org/how-to-do-microdermabrasion-at-home-expert-advice/ Some skin care is best left to the pros. Certain types of peels. lasers and deeper levels of light therapy should be done by a knowledgeable and certified expert. However, at-home microdermabrasion is a treatment that, with proper research and careful instruction from your dermatologist, can deliver skin-smoothing benefits right from your bathroom. What is […]]]>

Some skin care is best left to the pros. Certain types of peels. lasers and deeper levels of light therapy should be done by a knowledgeable and certified expert. However, at-home microdermabrasion is a treatment that, with proper research and careful instruction from your dermatologist, can deliver skin-smoothing benefits right from your bathroom.

What is microdermabrasion?

According to a certified dermatologist based in New York Diane Madfès, microdermabrasion works by removing the top layer of the skin using a combination of suction and gentle abrasion. Certified dermatologist King Hadley, who is also based in New York City, told Elle.com that another microdermabrasion technique involves spraying “fine particles of aluminum oxide or sodium bicarbonate with a vacuum [or] sucking. “Meanwhile, Michèle Green, another certified dermatologist, based in New York City, claims that the applicators – that is, the handpieces – use microscopic diamond shavings to gently exfoliate. You can even buy skin care products infused with tiny crystals that mimic the effects of microdermabrasion machines, but more on that later.

What are the benefits of microdermabrasion?

“Microdermabrasion can be used to target and improve the appearance of a wide range of skin conditions, including fine lines and wrinkles, large pores, hyperpigmentation, dullness, and sun damage,” notes Dr Green. She also credits microdermabrasion with increasing the rate of cell turnover in the skin, which in turn increases collagen production. The result? Glowing skin and a smooth, healthy-looking complexion.

Should I do microdermabrasion at home?

Every dermatologist we spoke to agreed that the procedure is most effective when done by a professional. According to Dr. Green, this is because office devices are designed to be more powerful than home devices. In addition, she continues: “Professionals can guide the patient to the best possible outcome and know who is a good candidate and who is not. With that in mind, you can still easily perform microdermabrasion at home for gentler results.

Can any skin type get microdermabrasion?

There are a few things to keep in mind when determining if the treatment is right for you: “Although gentle at-home microdermabrasion is technically safe for all skin types, the darker the skin type, the greater the risk of Potential side effects like discoloration is high. “Says New York-based Certified Dermatologist and Founder of OptiSkin Orit Markowitz. During this time, Marina peredo, another New York-based certified dermatologist, advises people with compromised skin, such as active acne, rosacea, eczema, or atopic dermatitis, to avoid microdermabrasion. This is because treatment can exacerbate flare-ups and scaly skin.

How to do microdermabrasion at home?

Limit sun exposure before and after treatment. “You should avoid the sun and use sunscreen a week before treatment and a week after,” says Dr Corey L. Hartman, certified dermatologist and founder of Skin Wellness Dermatology in Birmingham, Alabama. He goes on to tell Elle.com: “Similar to an exfoliant, sun exposure and microdermabrasion can do more harm than good.” According to the dermatologist, the skin will be more sensitive after the treatment, making it more susceptible to sunburn and damage.

Clean in advance. According to Dr. Hartman, your skin should be clean and free of makeup, dirt, oil, and debris for optimal microdermabrasion results. Dr Madfes suggests using micellar water to cleanse, calling it a “wonderful” option for prepping the skin before microdermabrasion treatment.

Start low and slowly. “When using a home microdermabrasion machine, you should always start with the lowest setting to see how your skin responds,” says Dr. Peredo. “If you start out too aggressively, it can lead to acne, bruising or itchy skin,” she explains. Dr Madfes warns that this can also lead to enlarged pores.

Do your research before buying a device. While there are dozens of at-home microdermabrasion tools, Dr. Green recommends Microderm® by Trophy Skin. According to the dermatologist, the product offers a “gentle but deep exfoliation” thanks to its diamond tip applicator. In addition, the useful LCD screen displays an overview of the different treatment modes. It also comes with three interchangeable tips for peeling, extracting grime from pores, and infusing skin care products into the skin.

If you’d rather ignore the tool route, Dr Madfes suggests the Dr. Brandt Skincare Anti-Aging Microdermabrasion Scrub, which contains aluminum oxide crystals that smooth the skin and exfoliate Lactic acid and moisturizer jojoba oil.

Hydrate your skin. Once you’ve finished your microdermabrasion treatment, you’ll want to soothe the skin with a rich, nourishing moisturizer. Dr Green says that applying a face cream can help promote healing of the skin after treatment. she recommends Cetaphil Daily Moisturizing Lotion, which is formulated with hydrating hyaluronic acid. Alternatively, Dr. Hartman suggests Hydrating gel B5 SkinCeuticals, he says “bring immediately[s] skin hydration that may have been lost during treatment.

    Dr. Hartman also suggests using a “calming serum” after your home treatment. He recommends Good Molecules Niacinamide Serum since it is formulated with niacinamide. “The serum will help hydrate the skin and prolong some of the benefits of baby microdermabrasion. [looking] pores and a more even skin tone, ”says Dr. Hartman.

    Expect to see some changes. Don’t worry if your skin looks or feels different immediately and a few days after your treatment. According to Dr. King, your skin may feel tight and dry after treatment. You may also notice some redness. However, everything should be resolved “within 24 hours,” according to the dermatologist. Of course, if you notice any prolonged side effects, see your dermatologist to discuss them.

    What should I not do when doing microdermabrasion at home?

    Don’t over exfoliate. Excessive peeling can damage your skin. “Don’t overexfoliate a particular area of ​​the skin and don’t use your microdermabrasion machine too frequently, as this can potentially cause skin irritation, dryness, redness and swelling,” says Dr. Green. If you have oily skin, Dr. Green suggests performing microdermabrasion once every two weeks. People with normal skin can do the treatment once a month.

    Avoid going strong. When using a home microdermabrasion kit, be careful when applying pressure. “It can scratch the skin, causing redness and irritation,” says Dr. Hartman.

    Skip some products. Prepare your skin for microdermabrasion by changing your skin care routine in the days leading up to treatment. For example, Dr. Hartman advises avoiding retinoids, peels, or exfoliating treatments three days before microdermabrasion at home. Additionally, Dr. Markowitz recommends abstaining from vitamin C products at least a week before the procedure to avoid excessive irritation.

    Never go without SPF. Sunscreen is an essential part of every skincare routine, and it’s especially important after at-home microdermabrasion. “La Roche-Posay Anthelios Melting Sun Cream SPF 60 is a great option for comfortable and comprehensive broad spectrum coverage, ”says Dr. Green. She attributes to its formula rich in antioxidants nourishing, soothing and protecting the skin after the treatment.

    To be coherent. If you are giving a microdermabrasion injection, keep in mind that the results are temporary. “Patients who have microdermabrasion need to have monthly maintenance sessions to maintain their cosmetic results,” says Dr. Green.

    This content is created and maintained by a third party, and uploaded to this page to help users provide their email addresses. You may be able to find more information about this and other similar content on piano.io



Source link

]]>
Stock traders buy large volume of call options on Forte Biosciences (NASDAQ: FBRX) https://parentsofallergicchildren.org/stock-traders-buy-large-volume-of-call-options-on-forte-biosciences-nasdaq-fbrx/ Thu, 30 Dec 2021 23:38:12 +0000 https://parentsofallergicchildren.org/stock-traders-buy-large-volume-of-call-options-on-forte-biosciences-nasdaq-fbrx/ Forte Biosciences, Inc. (NASDAQ: FBRX) was the target of unusual options trading activity on Wednesday. Stock traders acquired 30,205 call options on the company. This represents an increase of 1,663% over the average volume of 1,713 call options. The NASDAQ FBRX traded up $ 0.04 on Thursday, reaching $ 2.12. The company had a trade […]]]>

Forte Biosciences, Inc. (NASDAQ: FBRX) was the target of unusual options trading activity on Wednesday. Stock traders acquired 30,205 call options on the company. This represents an increase of 1,663% over the average volume of 1,713 call options.

The NASDAQ FBRX traded up $ 0.04 on Thursday, reaching $ 2.12. The company had a trade volume of 433,733 shares, compared to its average volume of 1,747,113. The company’s fifty-day moving average price is $ 2.67 and its 200-day moving average price is $ 14.79. Forte Biosciences has a 12-month low of $ 1.96 and a 12-month high of $ 7.26.

Forte Biosciences (NASDAQ: FBRX) last announced its results on Thursday, November 18. The company reported ($ 0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($ 0.36) from ($ 0.18). On average, equity analysts expect Forte Biosciences to post EPS of -1.58 for the current fiscal year.

A number of institutional investors and hedge funds have recently changed their positions in the company. BlackRock Inc. increased its stake in Forte Biosciences by 196.2% during the 2nd quarter. BlackRock Inc. now owns 775,119 shares of the company valued at $ 26,059,000 after purchasing an additional 513,450 shares during the last quarter. Point72 Asset Management LP strengthened its position in Forte Biosciences shares by 33.6% during the second quarter. Point72 Asset Management LP now owns 668,449 shares of the company valued at $ 22,473,000 after acquiring an additional 168,249 shares during the last quarter. Vanguard Group Inc. strengthened its position in Forte Biosciences shares by 17.2% during the 2nd quarter. Vanguard Group Inc. now owns 526,518 shares of the company valued at $ 17,701,000 after acquiring an additional 77,225 shares during the last quarter. Woodline Partners LP strengthened its position in Forte Biosciences shares by 1.8% during the second quarter. Woodline Partners LP now owns 193,663 shares of the company valued at $ 6,511,000 after acquiring an additional 3,348 shares during the last quarter. Finally, State Street Corp acquired a new position in shares of Forte Biosciences during the second quarter valued at approximately $ 6,105,000. 69.79% of the shares are currently held by institutional investors.

(A d)

SpaceX (and many other tech giants) are buying helium like crazy. And that’s because the world is running out of this incredibly precious gas! Indeed, prices have already climbed 160% in recent years …

A number of analysts have recently weighed on the title. LADENBURG THALM / SH SH reduced Forte Biosciences shares from a “buy” rating to a “neutral” rating in a report released on Friday, September 3. Truist Securities downgraded Forte Biosciences shares from a “buy” rating to a “custody” rating in a Friday September 3 research note. Truist reduced Forte Biosciences shares from a “buy” rating to a “hold” rating in a research note on Friday, September 3. Zacks Investment Research downgraded Forte Biosciences shares from a “buy” rating to a “hold” rating in a research note on Friday, November 19. Finally, B. Riley downgraded Forte Biosciences shares from a “buy” rating to a “neutral” rating in a research note on Friday, September 3. One research analyst rated the stock with a sell rating, eight issued a conservation rating, and another assigned a buy rating to the stock. According to MarketBeat.com, Forte Biosciences currently has a consensus rating of “Hold” and an average price target of $ 64.13.

About Forte Biosciences

Forte Biosciences, Inc. is a clinical-stage, dermatology-focused biopharmaceutical company. The company’s flagship product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A.

Featured article: What is the impact of upfront charges on an investment?

This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in Forte Biosciences right now?

Before you consider Forte Biosciences, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold of … and Forte Biosciences was not on the list.

While Forte Biosciences currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better bets.

See the 5 actions here


Source link

]]>
BioMe Inc. and Yonsei Medical Center sign technology https://parentsofallergicchildren.org/biome-inc-and-yonsei-medical-center-sign-technology/ Wed, 29 Dec 2021 16:00:00 +0000 https://parentsofallergicchildren.org/biome-inc-and-yonsei-medical-center-sign-technology/ SEOUL, South Korea, December 29, 2021 (GLOBE NEWSWIRE) – The microbiome treatment market is receiving global attention and is rapidly emerging as a new treatment alternative for various incurable diseases. However, recent reports of failed clinical trials and the limitation of identifying a clear mode of action require a cautious approach. Korean company BioMe Inc. […]]]>

SEOUL, South Korea, December 29, 2021 (GLOBE NEWSWIRE) – The microbiome treatment market is receiving global attention and is rapidly emerging as a new treatment alternative for various incurable diseases. However, recent reports of failed clinical trials and the limitation of identifying a clear mode of action require a cautious approach. Korean company BioMe Inc. wants to disrupt the process with breakthrough microbiome-based therapies.

Founded in November 2020 by Professor Sang Sun Yoon of the Department of Microbiology and Immunology, Yonsei University College of Medicine, BioMe Inc. has developed a living biotherapeutic product (LBP) based on the microbiome. Based on the prestigious microbiology research foundation of Yonsei University College of Medicine, BioMe Inc.

(i) understand the bacteriological characteristics of candidate strains,

(ii) can prove its effectiveness using animal disease models, made possible in Avison’s state-of-the-art biomedical research center.

To speed up its research and development process, the startup recently signed a technology transfer contract with Yonsei University College of Medicine. BioMe Inc. would begin developing microbiome-based therapies with the six patents transferred from Yonsei University College of Medicine.

The technology transfer under the contract includes a total of six patents, and BioMe’s development pipeline is as follows:

No. Development pipeline
1 A protein derived from the respiratory tract microbiome with inhibitory effects against broad-spectrum respiratory infections
2 An immune system boosting protein derived from the microbiome with a clear anticancer effect
3 An effective skin microbiome in the treatment of atopic dermatitis
4 A consortium of commensal microbes showing their effectiveness in treating inflammatory bowel disease
5 New symbiotic system inducing butyrate synthesis

In addition to the above technology, a new pipeline capable of degrading TMA, a risk factor for cardiovascular disease, is under development by BioMe Inc.

Beyond finding useful strains, BioMe Inc. is building a microbiome-based system that selectively produces beneficial metabolites or degrades their dangerous counterparts. This development strategy represented by “Molecule First” is implemented through the iBTSMT (Integrated BioMe Technology for Screen).

Recently, Kim Bu Seon, former Managing Director of SK Bioscience, was recruited to design target product profiles for candidate strains. Preclinical trials are expected to begin in the first half of 2022 and clinical trials will begin in 2023.

Press contact: valabh@topprwire.com

Related images

Image 1: BioMe

BioMe

This content was posted through the press release distribution service at Newswire.com.


Source link

]]>
Does atopic dermatitis have an increased risk of acquiring COVID-19? https://parentsofallergicchildren.org/does-atopic-dermatitis-have-an-increased-risk-of-acquiring-covid-19/ Tue, 28 Dec 2021 00:23:11 +0000 https://parentsofallergicchildren.org/does-atopic-dermatitis-have-an-increased-risk-of-acquiring-covid-19/ Based on the best available evidence, patients with atopic dermatitis (AD) do not appear to face an increased risk of contracting COVID-19 or being hospitalized because of the virus. “This is an area that will continue to evolve, and better understanding will improve the health advice we provide to our patients,” said Jacob P. Thyssen, […]]]>

Based on the best available evidence, patients with atopic dermatitis (AD) do not appear to face an increased risk of contracting COVID-19 or being hospitalized because of the virus.

“This is an area that will continue to evolve, and better understanding will improve the health advice we provide to our patients,” said Jacob P. Thyssen, MD, PhD, DmSci, at the Revolutionizing Atopic Dermatitis Virtual Symposium. “The general recommendation for now is to continue systemic treatments for AD during the pandemic, but the risk of acquiring COVID-19 is different for different drugs. “

According to Thyssen, professor of dermatology at the University of Copenhagen, Denmark, early management advice from the European Atopic Dermatitis Working Group (ETFAD), the European Academy of Allergy and Clinical Immunology (EAACI) and the International Eczema Council (IEC) say patients with AD who take biologics or immunosuppressants should continue treatment if they are not infected with COVID-19. For example, the EIC statement states that the IEC “does not recommend the temporary discontinuation of systemic treatments for AD affecting the immune system in patients without COVID-19 infection, or in those with COVID- 19 but are asymptomatic or have only mild symptoms ”.

EAACI guidelines recommend patients with AD who are infected with COVID-19 to withhold biologic therapy for at least 2 weeks until they have recovered and / or have a SARS-CoV-2 test negative.

“However, if you have a more serious respiratory illness, the advice for dermatologists is to see an infectious medicine specialist or pulmonologist,” Thyssen said. “It is outside our area of ​​expertise. But in terms of AD, there is no reason to stop treatment as long as the patient has mild symptoms or is asymptomatic. AD patients treated with immunosuppressive agents may have a higher risk of complications from COVID-19. Treatment with traditional immunosuppressive drugs increases risk of infections. But what about COVID-19? “

Traditional systemic immunosuppressive therapies in AD with azathioprine, cyclosporine and methotrexate suppress the immune system for 1 to 3 months, Thyssen continued. “We know that the vaccine response is reduced when using these agents,” he said. “The half-life of dupilumab [Dupixent] is 12-21 days. It takes about 13 weeks before dupilumab is completely cleared from the system, but it is such a targeted therapy that it does not lead to systemic immunosuppression. “

During this time, the half-life of JAK inhibitors such as baricitinib (Olumiant) is approximately 13 hours. “It’s a broader immunosuppressant because there will be off-target effects if you have a high dose, but it’s much more specific than traditional immunosuppressants,” he said. “We now have JAK1 and JAK2 inhibitors in AD, which do not interfere with vaccine responses to the same degree as traditional immunosuppressants.”

To assess the risk of COVID-19 in patients with AD, researchers at the Center for Dermatology Research at the University of Manchester, UK, conducted a cross-sectional study of 13,162 dermatology patients seen in the UK between June 2018 and February 2021. of the 13,162 patients, 624 (4.7%) had AD. They found that 4.8% of patients without a history of COVID-19 infection had AD, compared with 3.4% with a history of COVID-19. The risk of COVID-19 in patients with AD was similar to that of controls (adjusted odds ratio, 0.67).

The authors of a separate cross-sectional study published in May assessed the health insurance medical records of 269,299 patients who were tested for SARS-CoV-2 at University of California medical centers. Of these, 3.6% tested positive for SARS-CoV-2. Of 5,387 patients with AD, the infection rate was 2.9%, which was lower than that of patients without AD (3.7%; P = .0063). Hospitalization and mortality did not increase in patients with AD.

Another study, a case-control study of over 4.6 million HMO patients in Israel, found that taking systemic corticosteroids, advanced age, comorbid cardiovascular disease, metabolic syndrome and COPD were independent predictors of hospitalization associated with COVID-19. Mortality from COVID-19 has been independently predicted by metabolic syndrome and COPD, but not by variables related to AD.

“So for our AD patients there is no need to worry that they will develop COVID-19 infection or have a severe course, but we have a few drugs that would slightly increase the risk,” Thyssen said. .

In another analysis, researchers assessed data derived from Symphony Health’s COVID-19 research database to assess the risk of COVID-19 infection in adults with AD. The AD cohort consisted of 39,417 patients and the non-AD cohort comprised 397,293 patients. Of the AD patients, 8,180 received a prescription for prednisone, 2793 received a prescription for dupilumab, 714 received a prescription for methotrexate, and 512 received a prescription for cyclosporine. The risk of COVID-19 was slightly increased in the AD cohort compared to the non-AD cohort (adjusted incidence rate ratio [IRR], 1.18; P <.0001).

“There can be various explanations for this,” Thyssen said. “I still think we should maintain that AD on its own is not a risk factor for COVID-19, but some of the drugs may slightly increase the risk.”

In other results, investigators observed that treatment with dupilumab compared to no systemic drug reduced the risk of COVID-19 by 34% (adjusted IRR: 0.66; P <0.0001), as well as 18% methotrexate (IRR adjusted 0.82; P = .32). However, compared to no systemic drug use, the use of prednisone slightly increased the risk of COVID-19 (Adjusted IRR, 1.13; P = 0.03), as was the use of cyclosporine (adjusted IRR, 1.20; P = 0.32) and azathioprine (adjusted IRR, 1.61; P =. 16).

More recently, researchers evaluated the records of 1,237 patients with moderate to severe AD (aged 9 to 95 years) to assess the self-reported severity of COVID-19 symptoms among those who received dupilumab compared to others. treatments.

Of the 1237 patients with AD, 632 were on dupilumab, 107 were on other systemic treatments, and 498 were on little or no treatment. Patients treated with dupilumab were less likely to report moderate to severe symptoms of COVID-19 compared to patients taking other systemic treatments, or limited or no treatments.

Vaccines and AD

Thyssen pointed out that the risk-benefit ratio of currently approved COVID-19 vaccines is better than the risk of infection with SARS-CoV-2. “AD is not a contraindication to vaccination,” he said. “The COVID-19 vaccine does not cause worsening of AD because the vaccine response is mainly biased by Th1. He added that systemic immunosuppressants and JAK inhibitors used to treat AD may attenuate the vaccine response, but no attenuation is expected with dupilumab. “The half-life of JAK inhibitors is so short that vaccination followed by a week of treatment break is a good strategy for patients.”

Thyssen has revealed that he is a speaker, advisory board member and / or investigator for Asian, Arena, Almirall, AbbVie, Eli Lilly & Co., LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme.

The Revolutionizing Atopic Dermatitis Symposium. December 11-13, 2021.

Doug Brunk is an award-winning San Diego-based reporter for MDedge and Medscape who began covering healthcare in 1991. He is the author of two books related to the University of Kentucky Wildcats men’s basketball program. .

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube and LinkedIn



Source link

]]>